Georgina Meneses‐Lorente

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

Philippe A. Cassier, Antoîne Italiano, Carlos Gomez-Roca et al. · The Lancet Oncology · 2015 · 356 citations

Medicine, Immunology, Pathology +9

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

C. Gomez-Roca, Antoîne Italiano, Christophe Le Tourneau et al. · Annals of Oncology · 2019 · 189 citations · Full text

Immunosuppressive M2-like Macrophages, Medicine, Metronomic Therapy +6

Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)

Ami V. Desai, Giles Robinson, Karen Gauvain et al. · Neuro-Oncology · 2022 · 121 citations · Full text

Multiplex proteomic analysis by two‐dimensional differential in‐gel electrophoresis

Michael R. Knowles, Sandra Cervino, Heather A. Skynner et al. · PROTEOMICS · 2003 · 118 citations · Full text

Molecular Biology, Proteomic Technology, Experimental Neuropathology +17

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin et al. · Journal for ImmunoTherapy of Cancer · 2022 · 93 citations · Full text